Original scientific paper
Platelet resistance to anti-aggregating effect of acetylsalicylic acid in solid tumor patients
Miroslav Banović
; Department of Transfusiology and Hemostasis, University Hospital for Tumors, Zagreb, Croatia
Gorana Krajačić-Karas
; Department of Transfusiology and Hemostasis, University Hospital for Tumors, Zagreb, Croatia
Irena Veliki-Dalić
; Department of Pathology, University Hospital for Tumors, Zagreb, Croatia
Marija Lovrić
; University Hospital for Tumors, Zagreb, Croatia
Miro Banović
; School of Medicine, University of Rijeka, Rijeka, Croatia
Abstract
The anti-aggregating effect of acetylsalicylic acid (ASA 100 mg/day and 200 mg/day) was monitored in platelets of 351 solid tumor patients. As ASA increases the aggregation time, its anti-aggregating effect plays an important role in the prevention of thrombosis. Measurements were performed using the Siemens PFA 100 aggregometer with a collagen/EPI test cartridge. The mean age of patients was 64.33 ± 11.67 years. Among them, there were 74 (21.08%) male and 277 (78.91%) female patients suffering from head and neck tumors - 34 pts (9.69% ), breast cancer - 222 pts (63.2%), lung cancer - 4 pts (1.14%), abdominal cancer - 54 pts (15.4% ), urinary - 4 pts (1.14%), and genital tract cancer - 33 pts (9.4% ). Aggregation levels >160 seconds show the ASA effect on circulating platelets. The anti-aggregating effect of ASA 100 mg/day reported in 142 (40%) pts was absent in 209 (60%) pts. The mean anti-aggregating effect of ASA 100 mg/day for male and female patients was 169.29 ± 79.54 and 168.51 ± 69.71 seconds, respectively. No statistically significant difference was found between the male and female platelet aggregation results (p = 0.759). Interindividual variability in aggregation profiles was observed with the coefficient of variation CV = 41-47%. From the group not responding to ASA 100 mg/day, 40 patients were singled out to receive ASA 200 mg/day; of them 17 (42%) were responsive, and 23 (58%) patients were not responsive. No statistically significant difference was found between the two measurements carried out on samples from the same 38 patients with a 1-month interval (p = 0.063) to show the intraindividual stability of platelet aggregation. Whereas the antiaggregating effect of both ASA 100 mg/day and 200 mg/day has been shown in only 40% patients, dose tailoring based on the individual aggregation result is recommended.
Keywords
tumors; aggregation resistance; acetylsalicylic acid; PFA-100 aggregometer
Hrčak ID:
278703
URI
Publication date:
30.11.2009.
Visits: 616 *